MMIRF
Price
$0.05
Change
+$0.04 (+400.00%)
Updated
Jul 22 closing price
Capitalization
38.69M
SAGE
Price
$8.80
Change
+$0.04 (+0.46%)
Updated
Jul 25 closing price
Capitalization
551.08M
10 days until earnings call
Interact to see
Advertisement

MMIRF vs SAGE

Header iconMMIRF vs SAGE Comparison
Open Charts MMIRF vs SAGEBanner chart's image
Medmira
Price$0.05
Change+$0.04 (+400.00%)
Volume$1.5K
Capitalization38.69M
Sage Therapeutics
Price$8.80
Change+$0.04 (+0.46%)
Volume$2.93M
Capitalization551.08M
MMIRF vs SAGE Comparison Chart in %
Loading...
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MMIRF vs. SAGE commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MMIRF is a Buy and SAGE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (MMIRF: $0.05 vs. SAGE: $8.80)
Brand notoriety: MMIRF and SAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MMIRF: 18% vs. SAGE: 126%
Market capitalization -- MMIRF: $38.69M vs. SAGE: $551.08M
MMIRF [@Biotechnology] is valued at $38.69M. SAGE’s [@Biotechnology] market capitalization is $551.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MMIRF’s FA Score shows that 1 FA rating(s) are green whileSAGE’s FA Score has 1 green FA rating(s).

  • MMIRF’s FA Score: 1 green, 4 red.
  • SAGE’s FA Score: 1 green, 4 red.
According to our system of comparison, MMIRF is a better buy in the long-term than SAGE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MMIRF’s TA Score shows that 3 TA indicator(s) are bullish while SAGE’s TA Score has 4 bullish TA indicator(s).

  • MMIRF’s TA Score: 3 bullish, 4 bearish.
  • SAGE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SAGE is a better buy in the short-term than MMIRF.

Price Growth

MMIRF (@Biotechnology) experienced а +257.86% price change this week, while SAGE (@Biotechnology) price change was -3.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

MMIRF is expected to report earnings on Jul 01, 2025.

SAGE is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SAGE($551M) has a higher market cap than MMIRF($38.7M). MMIRF YTD gains are higher at: 282.443 vs. SAGE (62.063). MMIRF has higher annual earnings (EBITDA): -3.24M vs. SAGE (-358.98M). SAGE has more cash in the bank: 424M vs. MMIRF (18.3K). MMIRF has less debt than SAGE: MMIRF (10.2M) vs SAGE (11.9M). SAGE has higher revenues than MMIRF: SAGE (47.4M) vs MMIRF (254K).
MMIRFSAGEMMIRF / SAGE
Capitalization38.7M551M7%
EBITDA-3.24M-358.98M1%
Gain YTD282.44362.063455%
P/E RatioN/AN/A-
Revenue254K47.4M1%
Total Cash18.3K424M0%
Total Debt10.2M11.9M86%
FUNDAMENTALS RATINGS
MMIRF vs SAGE: Fundamental Ratings
MMIRF
SAGE
OUTLOOK RATING
1..100
4655
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
31
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3655
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MMIRF's Valuation (5) in the null industry is in the same range as SAGE (31) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew similarly to SAGE’s over the last 12 months.

MMIRF's Profit vs Risk Rating (100) in the null industry is in the same range as SAGE (100) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew similarly to SAGE’s over the last 12 months.

SAGE's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as MMIRF (100) in the null industry. This means that SAGE’s stock grew similarly to MMIRF’s over the last 12 months.

MMIRF's Price Growth Rating (36) in the null industry is in the same range as SAGE (55) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew similarly to SAGE’s over the last 12 months.

SAGE's P/E Growth Rating (97) in the Pharmaceuticals Other industry is in the same range as MMIRF (100) in the null industry. This means that SAGE’s stock grew similarly to MMIRF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MMIRFSAGE
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
64%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
52%
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
57%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
N/A
Bullish Trend 16 days ago
77%
Declines
ODDS (%)
N/A
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SCINX60.67N/A
N/A
DWS CROCI International S
WFINX57.87N/A
N/A
Allspring Index C
NELIX64.31N/A
N/A
Nuveen Equity Long/Short I
UPDDX23.07N/A
N/A
Upright Growth & Income
INGFX36.18N/A
N/A
Invesco Oppenheimer International Gr R5

MMIRF and

Correlation & Price change

A.I.dvisor tells us that MMIRF and NWPHF have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MMIRF and NWPHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MMIRF
1D Price
Change %
MMIRF100%
N/A
NWPHF - MMIRF
30%
Poorly correlated
N/A
TECX - MMIRF
29%
Poorly correlated
+0.18%
AZTR - MMIRF
24%
Poorly correlated
-4.34%
SRPT - MMIRF
22%
Poorly correlated
-7.38%
SAGE - MMIRF
22%
Poorly correlated
+0.46%
More

SAGE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAGE has been loosely correlated with CBIO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SAGE jumps, then CBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAGE
1D Price
Change %
SAGE100%
+0.46%
CBIO - SAGE
42%
Loosely correlated
+2.07%
AXON - SAGE
42%
Loosely correlated
+3.63%
PHIO - SAGE
42%
Loosely correlated
+9.16%
HRMY - SAGE
38%
Loosely correlated
+2.21%
BBIO - SAGE
36%
Loosely correlated
+1.40%
More